Indeed, most of the FDA-approved MS disease-modifying treatments have previously shown efficacy in EAE, including interferon beta, glatiramer acetate, natalizumab, sphingosine 1-phosphate modulators, dimethyl fumarate, and B cell depletion therapies [28]. The gene discussed is IFNB1; the disease is myeloid sarcoma.